hotspot -WSS

hotspot

author：entertainment 2025-10-01 18:07:34 - browse：179

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

Roche drug slashes death risk in early

Why you shouldn’t ask, “What country has the best health care?”

Merck, Johnson & Johnson CEOs will testify on high drug prices

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Summit: Ending the crisis of Black deaths in the U.S.

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Investment in vaccine development is lagging, report finds

Medicare details structure of new drug price negotiation program

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Cancer drug shortages should be causing more outrage

J&J lung cancer data amount to new salvo against AstraZeneca

Affirmative action in medical school literally saved lives

J&J lung cancer data amount to new salvo against AstraZeneca

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Summit: Ending the crisis of Black deaths in the U.S.

knowledge

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: Ending the crisis of Black deaths in the U.S.

Venture capital firm's plans to take over Akron hospital face hurdles

Venture capital firm's plans to take over Akron hospital face hurdles

Biogen walks away from Aduhelm, years after polarizing approval

New clues to why women have higher risk of autoimmune disorders

hotspot

hotspot

hotspot

explore